Blincyto's label has gradually been extended since 2014, and in December the MHRA approved it as the first immunotherapy for ...
Shares of Amgen Inc. AMGN advanced 1.24% to $297.93 Thursday, on what proved to be an all-around dismal trading session for ...
Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...
CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars: On January 30, 2025, the European Medicines Agency (EMA) Committee ...
A substantial insider sell was reported on February 7, by Nancy A Grygiel, SVP & CCO at Amgen AMGN, based on the recent SEC filing. What Happened: Grygiel's recent move involves selling 1,589 ...
Trump has set the European Union as his next target ... Top executives at big branded drugmakers including Merck , Amgen and Bristol-Myers said this week the impact of the 10% China tariffs on them ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...
All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up just over 7% since hitting a bottom in late December. The better-than ...
Zacks.com on MSN15d
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe UpdateAstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus Estimate of $1.07. Core earnings of $2.09 per share rose 44% year over ...
16d
Experts will explore AI-driven healthcare innovation and strategies to enhance patient engagement DIA, a global non-profit organization of life sciences professionals, will unite stakeholders from ...
Bristol Myers Squibb lays off 67 staffers in NJ: The company is letting go of 67 workers in Lawrence Township between April and December, according … ...
16d
Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback